Clearmind Medicine (CMND) announced the publication of a European patent application with the European Patent office for its innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct. The patent application refers to Clearmind’s successful collaboration with SciSparc. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, including Palmitoylethanolamide
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- SciSparc announces publication of European patent application
- Clearmind Medicine granted patent for binge behavior treatment by Macau
- Rising High: Innovative Industrial reports PharmaCann default
- Clearmind Medicine to move forward with MEAI-based alcohol substitute
- Clearmind Medicine receives IRB approval for Phase I/IIa trial of CMND-100